Respuesta inmune humoral a cuatro vacunas contra el SARS-CoV-2 en profesionales de la salud

Pareja Cruz*, Arturo; Luque Espino, Julio César; Navarrete Mejía, Pedro Javier; de León Delgado, Joel; Gonzáles Moscoso, Jesús Demóstenes.
Horiz. med. (Impresa) ; 22(2)abr. 2022.
Artículo en Español | LILACS-Express | ID: biblio-1448376

Documentos relacionados

  1. Antibody-independent protection against heterologous SARS-CoV-2 challenge conferred by prior infection or vaccination.
  2. SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase.
  3. SARS-CoV-2 humoral immune response in patients with cardiovascular risk factors: The COmmunity Cohort Study.
  4. Spheromers reveal robust T cell responses to the Pfizer/BioNTech vaccine and attenuated peripheral CD8<sup>+</sup> T cell responses post SARS-CoV-2 infection.
  5. ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19.
  6. Streamlining cross-border shipping of live invertebrates.
  7. Self-Boosting Vaccination Based on Pulsatile Antigen Release from Core-Shell Microparticles.
  8. A temperature-dependent virus-binding assay reveals the presence of neutralizing antibodies in human cytomegalovirus gB vaccine recipients' sera.
  9. [Anaphylaxis caused by vaccines].
  10. Efficacy of antibody response following the vaccination of SARS-CoV-2 infected and noninfected healthcare workers by two-dose inactive vaccine against COVID-19.